Hi, mooers!
Welcome back to Maple Market Challenge!  
Like always, let's reveal the answer to last week's quiz: What event on September 19 could drive Faraday Future's growth? The answer is China-U.S. Automotive Bridge Strategy.
A big round of applause to those who got it right! Each of you will receive 20 points. Plus, we're giving 50 points to everyone who left a comment. Well done, everyone! A private message with...

Hi, mooers!
Welcome back to Maple Market Challenge!  
Like always, let's reveal the answer to last week's quiz: At what price per share is Scotiabank acquiring the stake in KeyCorp? The answer is $17.17.
A big round of applause to those who got it right! Each of you will receive 20 points. Plus, we're giving 50 points to everyone who left a comment. Well done, everyone! A private message with...

Hi, mooers!
Welcome back to Maple Market Challenge!  
Like always, let's reveal the answer to last week's quiz: What impact did Elon Musk's endorsement of Donald Trump have on Tesla's stock price? The answer is 'surged more than 5%'.
A big round of applause to those who got it right! Each of you will receive 20 points. Plus, we're giving 50 points to everyone who left a comment. Well done, e...

$NewAmsterdam Pharma (NAMS.US)$ ⭕NewAmsterdam Pharma（NAMS）周一表示，对于家族性高胆固醇血症杂合子患者潜在降低胆固醇的药物obicetrapib的3期临床研究已达到主要终点，但是，股价却在消息发布后跌超8%，为此，找到相关本次临床相关信息以便进一步评估其下跌：
🔺obicetrapib是用于治疗低密度脂蛋白胆固醇（“LDL-C”）升高且有心血管疾病（“CVD”）风险的患者，这些患者现有疗法效果不够好或耐受性不佳
🔺本次临床试验的对象及其入选条件
Study Overview
Brief Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hyper...

$Apple (AAPL.US)$ is expected to release its Q2 FY 2024 earnings report on Thursday, May 2, after the market closes. So far this year, the tech giant has faltered by almost 12%, significantly lagging behind the $S&P 500 Index (.SPX.US)$ and its Mag 7 peers, except for $Tesla (TSLA.US)$. As analysts express apprehension regarding the company's challenges in China, ambiguity surrounding...